Paper Details

  1. Home
  2. Paper Details

The moderate intestinal side effects of auranofin do not require prophylactic therapy with a bulkforming agent. Dutch Ridaura Study Group.

Author: CouvéeJ E, FranssenM J, GijzelW P, van BeusekomH J, van ValburgJ A, van de LaarM A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Auranofin, a drug used to treat rheumatoid arthritis, can cause diarrhea and loose stools in up to 50% of patients. This study investigated whether a bulk-forming agent could reduce these side effects. While a slight improvement in stool consistency was observed in the bulk-forming group, the overall incidence of diarrhea remained similar to the placebo group. The results suggest that a bulk-forming agent is not beneficial in reducing auranofin-induced diarrhea, and that increasing the auranofin dosage might be a better option to enhance its efficacy.
Paper Details　
Original Abstract of the Article :
Incidences of diarrhoea and loose stools are reported up to 50% in patients starting treatment with auranofin. Moreover, +/-4% of patients discontinue treatment because of severe diarrhoea. We investigated whether a water binding agent would diminish the incidence of loose stools and diarrhoea. Endp...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF02238940

データ提供：米国国立医学図書館（NLM）

Auranofin: Navigating the Desert of Side Effects

Auranofin, a drug used to treat rheumatoid arthritis (RA), can sometimes be like a camel trek through the desert—filled with potential challenges and side effects. This research investigates the use of a bulk-forming agent, psyllium fibers, to mitigate the intestinal side effects of auranofin. Researchers aimed to determine if a bulk-forming agent could reduce the incidence of diarrhea and loose stools associated with auranofin treatment. The study provides valuable insights into managing the side effects of auranofin and optimizing treatment outcomes.

A Desert Oasis of Comfort: Minimal Benefit of Bulk-Forming Agents

The study reveals that the addition of a bulk-forming agent, psyllium fibers, did not significantly reduce the incidence of diarrhea and loose stools associated with auranofin treatment. This finding suggests that a bulk-forming agent may not be necessary as a prophylactic measure for auranofin-induced gastrointestinal side effects. The study provides valuable information for healthcare professionals seeking to manage the side effects of auranofin treatment.

A Desert Oasis of Relief: Managing Auranofin's Side Effects

This research offers practical guidance for managing the side effects of auranofin treatment, highlighting that a bulk-forming agent may not be necessary to mitigate gastrointestinal discomfort. The study underscores the importance of careful monitoring and individualizing treatment strategies to optimize patient outcomes. This research provides a roadmap for navigating the challenges of auranofin treatment, ensuring a more comfortable journey for patients.

Dr. Camel's Conclusion

Auranofin, like a camel trek through the desert, can have its share of unexpected side effects. This research helps us navigate the potential challenges of auranofin treatment by demonstrating that a bulk-forming agent may not be necessary to mitigate gastrointestinal discomfort. It emphasizes the importance of careful monitoring and individualizing treatment strategies to optimize patient outcomes.

Date :
  1. Date Completed 1997-11-20
  2. Date Revised 2019-09-09
Further Info :

Pubmed ID

9348142

DOI: Digital Object Identifier

10.1007/BF02238940

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.